Filip Dubovsky
Trustee
Filip Dubovsky is a pediatric infectious disease specialist and public health physician with extensive experience in developing vaccines and treatments for serious infections. Before joining the Sabin Board of Trustees, he served as President of Research and Development and Chief Medical Officer at Novavax, where he led the development and global approval of COVID-19 vaccines based on recombinant protein technology.
Dr. Dubovsky spent many years at MedImmune/AstraZeneca, holding roles such as Clinical Therapeutic Area Head for Infectious Diseases and Vaccines, and Deputy Chief Medical Officer for Clinical Affairs. During this time, he contributed to the development of vaccines and treatments for a range of diseases, including influenza, RSV, and infections caused by bacteria like Staphylococcus aureus and Pseudomonas aeruginosa. Earlier in his career, he worked at the PATH Malaria Vaccine Initiative, where he oversaw malaria vaccine research as the Scientific Director/Chief Scientist.
He holds a BA in cell biology from Cornell University, an MD from the University of Alabama in Birmingham, and an MPH in preventive medicine and vaccinology from Johns Hopkins School of Public Health. He also completed his pediatric training at Stanford University and specialized in tropical pediatrics and pediatric infectious diseases at the University of Maryland Center for Vaccine Development.
We make vaccines more accessible, enable innovation and expand immunization across the globe.